Vke schreef op 6 september 2016 07:31:
NIEUWS!!!
For best results when printing this announcement, please click on link below:
pdf.reuters.com/htmlnews/htmlnews.asp...Opens testing access to the largest state-run health plan in the United States
IRVINE, CA, and HERSTAL, BELGIUM - September 6, 2016 - MDxHealth SA (Euronext:
MDXH.BR) announced that the ConfirmMDx(®) for Prostate Cancer test is now
available as an in-network benefit under the California Medical Assistance
Program (Medi-Cal).
Medi-Cal is California's state-run Medicaid program, offering assistance to
individuals with low incomes. With nearly 12 million enrollees, it is the
single largest state-run public health program in the US. The agreement
extends access to ConfirmMDx for all Medi-Cal beneficiaries meeting the test
eligibility requirements. The Company will now seek to expand access to the
test through other Medicaid programs across the US.
"This agreement enhances our ability to deliver state-of-the-art diagnostic
testing to all sectors of the healthcare system in California, the largest
economy and most populous state in the US," stated Dr. Jan Groen, CEO of
MDxHealth. "This agreement provides a model for further expansion of coverage
in the US as health providers increasingly recognize the ability of ConfirmMDx
to improve patient outcomes and help manage rising healthcare costs."
About ConfirmMDx for Prostate Cancer
(http://www.mdxhealth.com/confirmmdx-prostate-cancer)
ConfirmMDx for Prostate Cancer is the first epigenetic, and only tissue-based
test in the 2016 NCCN Guidelines for early detection of prostate cancer which
addresses false negative biopsy concerns. It is the only molecular diagnostic
test that provides a very high negative predictive value (NPV) of 96% for
clinically significant prostate cancers, and 90% NPV for all prostate cancers,
as well as prostate mapping of the test results to help guide repeat biopsies.
Each year, more than 1 million American men undergo an invasive prostate
biopsy with a negative result, however approximately 30% of those men actually
have prostate cancer. The current standard of care for prostate biopsy
procedures samples less than 1% of the prostate, leaving men at risk for
undetected cancer and leading to a high rate of repeat biopsies, even on
cancer-free men. ConfirmMDx for Prostate Cancer helps urologists identify
low-risk men who may forego an unnecessary repeat biopsy and high-risk men who
may benefit from intervention. ConfirmMDx for Prostate Cancer helps urologists
identify low-risk men who may forego an unnecessary repeat biopsy and
high-risk men who may benefit from intervention. To date nearly 2,800
urologists have ordered ConfirmMDx on more than 45,000 patients. ConfirmMDx
has qualified for Medicare, Medicare Advantage and many private reimbursement
plans.
About MDxHealth (http://www.mdxhealth.com)
MDxHealth is a multinational healthcare company that provides actionable
molecular diagnostic information to personalize the diagnosis and treatment of
cancer. The company's tests are based on proprietary gene methylation
(epigenetic) and other molecular technologies and assist physicians with the
diagnosis of cancer, prognosis of recurrence risk, and prediction of response
to a specific therapy. For more information, visit mdxhealth.com
(http://www.mdxhealth.com/) and follow us on Twitter at: twitter.com/mdxhealth
(http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.twitter.com%2Fmdxhealth&esheet=50096965&lan=en-US&anchor=http%3A%2F%2Fwww.twitter.com%2Fmdxhealth&index=2&md5=2ac41a808a150aec8800a87f6f14b559).
For more information : Dr. Jan Groen, CEO MDxHealth US: +1 949 812 6979 BE: +32 4 364 20 70
info@mdxhealth.com Jonathan Birt, Chris Welsh, Hendrik Thys (PR & IR) Consilium Strategic Communications UK: +44 20 3709 5701 US: + 1 917 322 2571 (Rx Communications Group LLC)
mdxhealth@consilium-comms.com This press release contains forward-looking statements and estimates with
respect to the anticipated future performance of MDxHealth and the market in
which it operates. Such statements and estimates are based on assumptions and
assessments of known and unknown risks, uncertainties and other factors, which
were deemed reasonable but may not prove to be correct. Actual events are
difficult to predict, may depend upon factors that are beyond the company's
control, and may turn out to be materially different. MDxHealth expressly
disclaims any obligation to update any such forward-looking statements in this
release to reflect any change in its expectations with regard thereto or any
change in events, conditions or circumstances on which any such statement is
based unless required by law or regulation. This press release does not
constitute an offer or invitation for the sale or purchase of securities or
assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be
offered or sold within the United States without registration under the U.S.
Securities Act of 1933, as amended, or in compliance with an exemption
therefrom, and in accordance with any applicable U.S. securities laws.
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx and
PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other
trademarks and service marks are the property of their respective owners.
To access the PDF version, click here
(http://hugin.info/137314/R/2039572/760265.pdf)
This announcement is distributed by Nasdaq Corporate Solutions on behalf of
Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for
the content, accuracy and originality of the information contained therein.
Source: MDxHealth (R) via Globenewswire